N-boc-6-aminohexanoic acid | 1204475-39-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-boc-6-aminohexanoic acid
• 英文别名: 8-Aminooctan-3-one
• CAS: 1204475-39-7
• 化学式: C₈H₁₇NO
• 分子量: 143.229
• InChiKey: NDTZJRQHTUSVHJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  色胺 、 N-boc-6-aminohexanoic acid 、 [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-9-[3-[6-[6-[5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoylamino]hexanoylamino]propanoyloxy]-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1-hydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate 、 溴乙酸 在 哌啶 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 N-甲基吡咯烷酮 为溶剂， 生成
  参考文献：
  名称：

  Macrocyclic Peptoid–Peptide Hybrids as Inhibitors of Class I Histone Deacetylases

  摘要：

  We report the design, synthesis, and biological evaluation of the first macrocyclic peptoid-containing histone deacetylase (HDAC) inhibitors. The compounds selectively inhibit human class I HDAC isoforms in vitro, with no inhibition of the tubulin deacetylase activity associated with class IIb HDAC6 in cultured Jurkat cells. Compared to the natural product apicidin (1), one inhibitor (compound 10) showed equivalent potency against K-562 cells, but was more cytoselective across a panel of cancer cell lines.

  DOI：

  10.1021/ml300162r
• 作为产物：
  描述：

  在 三氟乙酸 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 为溶剂， 反应 1.5h， 生成 N-boc-6-aminohexanoic acid
  参考文献：
  名称：

  Macrocyclic Peptoid–Peptide Hybrids as Inhibitors of Class I Histone Deacetylases

  摘要：

  We report the design, synthesis, and biological evaluation of the first macrocyclic peptoid-containing histone deacetylase (HDAC) inhibitors. The compounds selectively inhibit human class I HDAC isoforms in vitro, with no inhibition of the tubulin deacetylase activity associated with class IIb HDAC6 in cultured Jurkat cells. Compared to the natural product apicidin (1), one inhibitor (compound 10) showed equivalent potency against K-562 cells, but was more cytoselective across a panel of cancer cell lines.

  DOI：

  10.1021/ml300162r

文献信息

• DRUG-LIGAND CONJUGATES, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO
  申请人：Chen Zhiyu

  公开号：US20130190475A1

  公开（公告）日：2013-07-25

  The present invention relates to methods for synthesizing compounds of formula I or pharmaceutically acceptable salts thereof: I wherein each of X, Alk 1 , Alk 2 , and W are as defined and described herein.

  本发明涉及合成式I化合物或其药用可接受盐的方法：其中X、Alk1、Alk2和W各自如本文所定义和描述。
• [EN] NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE<br/>[FR] NOUVEAUX LACTAMES FONCTIONNALISÉS COMME MODULATEURS DU RÉCEPTEUR 7 DE LA 5-HYDROXYTRYPTAMINE, ET PROCÉDÉ POUR LEUR UTILISATION
  申请人：UNIV TEMPLE

  公开号：WO2021097116A1

  公开（公告）日：2021-05-20

  Described herein are new, selective modulators of the 5 -HT7 receptor. These selective compounds can be useful for the treatment of CNS and non-CNS indications. Compounds described herein can be selective in targeting 5-HT7 receptors as compared to other receptors and/or by selective targeting 5-HT7 receptors expressed in certain tissues or organs, thereby effective selectivity through a particular partitioning profile of the 5- HT7 modulator.

  本文描述了5-HT7受体的新型选择性调节剂。这些选择性化合物可以用于治疗中枢神经系统和非中枢神经系统的适应症。本文描述的化合物可以在靶向5-HT7受体方面具有选择性，相对于其他受体或通过选择性靶向在某些组织或器官中表达的5-HT7受体而言，从而通过5-HT7调节剂的特定分区配置实现有效选择性。
• Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use
  申请人：Clairmont Kevin

  公开号：US20090280106A1

  公开（公告）日：2009-11-12

  This invention provides peptides with novel modifications that provide suitable derivatization sites to improve the pharmacokinetic properties of the peptides. These modified peptides function in vivo as agonists of the VPAC2 receptor. The peptides of the present invention provide a new therapy for patients with decreased endogenous insulin secretion, for example, type 2 diabetics.

  本发明提供了具有新颖修饰的肽，这些修饰提供了适合衍生化的位点，以改善肽的药代动力学特性。这些修饰后的肽在体内作为VPAC2受体的激动剂发挥作用。本发明的肽为具有内源性胰岛素分泌减少的患者，例如2型糖尿病患者提供了新的治疗方法。
• AMINOTHIAZOLES AND THEIR USES
  申请人：LaMarche Matthew J.

  公开号：US20100267757A1

  公开（公告）日：2010-10-21

  The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases.

  本申请描述了有机化合物，可用于治疗、预防和/或改善疾病。
• SYNTHETIC PENTASACCHARIDES HAVING SHORT HALF-LIFE AND HIGH ACTIVITY
  申请人：Carbomimetics

  公开号：EP2721044B1

  公开（公告）日：2015-11-18